Table 3.
Characteristics of patients transitioned from inhaled or parental prostanoids.
| Characteristic | n = 22 (78.6%) |
|---|---|
| Initial prostanoid | |
| Treprostinil | 21 (95.5) |
| Intravenous | 1 (4.8) |
| Subcutaneous | 5 (23.8) |
| Parenteral treprostinil dose (ng/kg/min) | 63 (40–118) |
| Inhaled | 15 (71.4) |
| Breaths/dose | 9 (6–10) |
| Doses per day | |
| Four times per day | 12 (80.0) |
| Three times per day | 3 (20.0) |
| Inhaled iloprost | 1 (4.5) |
| Doses per day of 2.5 mcg inhalations | 2–3 |
| Time on medication before transition (years) | 3.1 (2.1–4.5) |
| Reason for transition | |
| Patient preference | 17 (77.3) |
| Disease progression | 4 (18.2) |
| Adverse reaction to other medication | 3 (13.6) |
| Site pain (% of those receiving subcutaneous medication) | 3 (60) |
| Central line complications | 0 (0.0) |
| Transition venue | |
| Hospital ward | 2 (9.1) |
| Hospital intensive care unit | 2 (9.1) |
| Home | 18 (81.8) |
| Transition duration (home and hospital) (days) | 46 (6–64) |
| Hospital length of stay for those transitioned in hospital (days) | 7 (5–8) |
| Dose at end of transition (mg per dose) | 2.0 (1.4–3.0) |
| Final dosing interval | |
| Twice per day | 8 (36.4) |
| Three times per day | 14 (63.6) |
| Completed ≥7 days at goal dose | 21 (95.5) |
Values are given as n (%) or median (IQR).